If you or a loved one is taking Tysabri and concerned about PML, understanding the timeline between infusion and symptom onset is critical for early detection. Decades of pharmacovigilance research have established that PML risk increases with longer treatment duration and certain co-factors. This page explains what the FDA warning means for your health and what steps to take next.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML occurs in patients who are immunocompromised, and Tysabri’s mechanism of action—blocking lymphocyte trafficking to the central nervous system—is thought to impair immune surveillance, allowing JCV reactivation and spread. Clinical presentation of PML typically includes subacute neurological deficits such as cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. The FDA Adverse Event Reporting System (FAERS) lists Tysabri-associated events including cognitive disorder (3478 reports), memory impairment (7895 reports), and gait disturbance (9422 reports), which may overlap with early PML symptoms (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). However, PML itself is a distinct, often rapidly progressive condition. Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. The boxed warning emphasizes that healthcare professionals must monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires prescriber, patient, and pharmacy enrollment, as well as periodic evaluations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning explicitly states the risk and identifies risk factors, but questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, especially for those with longer treatment durations or prior immunosuppressant use. The TOUCH program mandates that patients be evaluated three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prescribers must submit status reports and reauthorization questionnaires every six months, and report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML cases have continued to occur, leading to litigation by affected patients or their families. For patients in Texas who developed PML after Tysabri use, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between exposure and documented harm can be variable. PML typically develops after months to years of Tysabri treatment, with risk increasing beyond two years. The onset of symptoms may be insidious, and diagnosis may be delayed, complicating the determination of when the injury was discovered. Patients who experience neurological symptoms such as cognitive changes, weakness, or visual problems should seek immediate medical evaluation, as early diagnosis and discontinuation of Tysabri may improve outcomes. Legal counsel can help assess whether the claim was filed within the applicable limitations period, considering the date of diagnosis or the date when the link to Tysabri was recognized.
The mechanistic pathway linking Tysabri to PML involves the drug’s inhibition of alpha-4 integrin, which prevents lymphocytes from crossing the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing JCV to replicate unchecked in oligodendrocytes, leading to demyelination and neuronal damage. The FAERS data show that Tysabri is associated with a range of neurological adverse events, but PML is the most serious, with a high rate of mortality and severe disability (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). Patients who survive PML often have permanent neurological deficits, including cognitive impairment, motor dysfunction, and visual loss. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and monitoring requirements outlined in its prescribing information. Patients in Texas who have been harmed by PML after Tysabri use should be aware of the statute of limitations and seek legal advice promptly. The adequacy of warnings and the timeline between exposure and harm are critical factors in any potential claim.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this can be complex due to the variable timeline between Tysabri exposure and diagnosis. It is crucial to consult an attorney promptly to determine if your claim falls within the limitations period.
Three established risk factors are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.
Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. Clinical presentation typically includes subacute neurological deficits such as cognitive decline, motor weakness, visual disturbances, and speech difficulties.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.